dasatinib

ACSL4-high blasts showed enhanced dasatinib sensitivity (r = -0.25, P = 4.3 x 10-8). Conversely, ACSL4-high blasts showed significant ex vivo resistance to venetoclax (r = 0.36, P = 2.5 x 10-12), linking the ferroptosis-primed monocytic state to BCL2 inhibitor failure. These findings nominate ACSL4-driven ferroptosis susceptibility as a lineage-specific vulnerability rendering monocytic AML selectively sensitive to SRC-directed therapy while resistant to BCL2 inhibition.

P2, N=25, Recruiting, University of Chicago | Suspended --> Recruiting | Trial completion date: Mar 2027 --> Mar 2028 | Trial primary completion date: Mar 2027 --> Mar 2028

Simultaneously, the controlled release of dasatinib inhibits CAF-mediated fibrosis, dismantling the stromal barrier, reducing tumor stiffness and facilitating the infiltration of cytotoxic T lymphocytes. This study establishes a precise piezocatalysis-driven strategy for reprogramming the tumor microenvironment in desmoplastic malignancies, providing a promising avenue for the development of two-dimensional nanomaterials in cancer immunotherapy.

P1, N=14, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting --> Recruiting

The patient had a history of CML treated with imatinib for 4 years, with loss of complete hematological response for 3 months before being diagnosed with RCC and lung metastases. Due to a T315I mutation in the BCR-ABL1 gene, the treatment regimen included a novel combination of Axitinib, Dasatinib, and low-dose nivolumab. The patient showed a remarkable therapeutic response with a complete metabolic response accompanied by a highly significant reduction in the size of the tumor and complete resolution of the metastatic lung lesions, as well as a major molecular response in terms of CML disease control.

Three patients were treated with imatinib (one later switched to nilotinib and then dasatinib), while one patient each received osimertinib and brigatinib. When interstitial pneumonia occurs during TKI administration and does not respond to drug withdrawal and corticosteroid treatment, careful analysis of chest imaging features, along with bronchoalveolar lavage and/or bronchoscopic lung biopsy, is necessary for a definitive diagnosis. This case series and literature review suggest that nebulized GM-CSF or whole lung lavage (WLL) may be effective treatment options for TKI-induced autoimmune PAP.

P3, N=5949, Completed, National Cancer Institute (NCI) | Trial completion date: Oct 2026 --> Mar 2026 | Active, not recruiting --> Completed

P2, N=30, Enrolling by invitation, Mayo Clinic | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027

The patient achieved complete hematological remission after one cycle of dasatinib combined with hyper-CVAD/MA. Measurable residual disease persisted, and he underwent two cycles of inotuzumab ozogamicin therapy followed by allogeneic hematopoietic stem cell transplantation. This case highlights the critical need for vigilant follow-up in CML patients after prolonged TFR, given the risk of progression to blast crisis.

Dasatinib induced deep molecular remission; however, persistent thrombocytosis required hydroxyurea. This case underscores the importance of vigilance for secondary myeloproliferative neoplasms (MPNs) and clonal evolution when a new hematologic phenotype emerges in a patient with an established MPN. The coexistence of JAK2 V617F and BCR::ABL1 mutations is exceedingly rare and presents significant diagnostic and therapeutic challenges.

P1/2, N=76, Recruiting, Medical University of South Carolina | Trial completion date: May 2027 --> May 2028 | Trial primary completion date: May 2026 --> May 2027

The case also contributes to the limited literature reporting systemic CMV infections associated with dasatinib. In addition, it extends the spectrum of reported dasatinib-associated infections to include Granulicatella adiacens.